Table 2. Test for the difference of the hypothyroidism reporting rate between sunitinib and sorafenib in the FDA adverse event reporting system (FAERS).

	Sunitinib	Sorafenib
Hypothyroidism Reported	287	55
Hypothyroidism Not Reported	16955	9579
Ratio of Hypothyroidism Report (%)	1.66	0.57
Odds Ratio (95% CI)	2.95 (2.21 − 3.94)
P-value*	2.86E-16

* One-tailed Fisher’s exact test was performed for the higher rate of hypothyroidism for sunitinib compared to sorafenib.